BiotechTube
Zero Point Five Therapeutics

Zero Point Five Therapeutics

Cambridge, United States· Est.
zeropointfivetherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $4M

Overview

Zero Point Five Therapeutics is an early-stage, private biotech leveraging small molecule chemistry to drug challenging protein-protein interactions, a historically difficult class of targets in oncology. Founded in 2020 and operating from the biotech hub of Cambridge, the company appears to be in a preclinical or discovery-stage research phase. While its core focus is oncology, the company's stated mission includes addressing neglected diseases, suggesting a potential dual therapeutic focus or a long-term strategic direction. Limited public information indicates it is likely pre-revenue and venture-backed.

OncologyNeglected Diseases

Technology Platform

Small molecule drug discovery platform focused on inhibiting challenging protein-protein interactions (PPIs).

Funding History

1
Total raised:$4M
Seed$4M

Opportunities

The successful development of a platform to drug PPIs with small molecules addresses a major unmet need in drug discovery, particularly in oncology.
This could lead to first-in-class therapies for high-value targets.
The additional focus on neglected diseases, while risky, could open non-dilutive funding avenues (e.g., grants from NGOs or government agencies like the NIH) and provide a differentiated strategic angle.

Risk Factors

The core scientific challenge of inhibiting PPIs with oral small molecules is extremely high, with a history of failure.
The company is at a very early stage with no disclosed pipeline, making progress difficult to assess.
As a pre-revenue startup, it is vulnerable to financing risks and may struggle to compete for talent and resources with larger, better-funded entities in the same space.

Competitive Landscape

ZP5 operates in the highly competitive field of oncology drug discovery and the specific niche of PPI inhibition. It competes with other biotechs using small molecules (e.g., Schrödinger, Relay Therapeutics), as well as those using alternative modalities like protein degraders (PROTACs from companies like Arvinas, Kymera Therapeutics) and biologics to target PPIs. Its focus on neglected diseases is less crowded but offers uncertain commercial returns.

More companies in United States →